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Abstract
Objective: To examine the relationship between cancer stage, surgical treatment and chemotherapy on
quality of life (QOL) after breast cancer and determine if sociodemographic characteristics modify the
observed relationships. Methods: A population-based sample of women with Stages 0–II breast cancer in
the United States (N ¼ 1357) completed surveys including the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and the Breast Cancer-Specific
Quality of Life Questionnaire (QLQ BR-23). Regression models calculated mean QOL scores across pri-
mary surgical treatment and chemotherapy. Clinically significant differences in QOL were defined as P10
point difference (out of 100) between groups. Results: Meaningful differences in QOL by surgical treatment
were limited to body image with women receiving mastectomy with reconstruction reporting lower scores
than women receiving breast conserving surgery (p < 0.001). Chemotherapy lowered QOL scores overall
across four QOL dimensions (p values < 0.001), with a disproportionately greater impact on those with
lower levels of education. Younger women reported lower QOL scores for seven of nine QOL dimensions (p
values < 0.001). Conclusions: Women should be reassured that few QOL differences exist based on surgical
treatment, however, clinicians should recognize that the impact of treatment on QOL does vary by a
woman’s age and educational level.
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Introduction
Treatment for early stage breast cancer consists of
surgery, followed by some combination of radia-
tion, chemotherapy, and/or hormone therapy;
with each treatment having the potential to alter
quality of life (QOL). The majority of women with
early stage breast cancer have three surgical choi-
ces that carry the same survival: breast conserving
surgery (BCS) with radiation, mastectomy only,
and mastectomy with reconstruction [1, 2]. Treat-
ment choices may be related to perceived differ-
ences in QOL among the procedures when survival
is equivalent. Interest is increasing on the impact
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of breast cancer stage and these various treatment
approaches on QOL, and if it differs across sub-
populations.
The differential QOL impact dependent on
cancer stage at diagnosis has not been well inves-
tigated, especially comparing women with invasive
vs. non-invasive disease. Amichetti et al. [3] found
that while women with ductal carcinoma in situ
(DCIS) treated with BCS expressed good physical
and social well-being, about 50% still reported a
medium level of depression and anxiety at 4 years
follow-up. More recently, Rakovitch et al. [4]
compared risk perception and psychological mor-
bidity in women with DCIS vs. invasive disease
and found no differences in perception of recur-
rence and similar levels of psychological distress in
the two groups.
Studies that have focused on surgery, have re-
ported few treatment-related differences in QOL
between BCS and mastectomy [5–10] with the
exception of less impact on body image with BCS
[6, 10–15]. Some studies have noted fewer sexual
problems with BCS [6, 11, 12, 14, 15], while others
report less fear of recurrence with mastectomy [16,
17, and N.K. Katz, personal correspondence]. The
impact of mastectomy on body image may be
reduced in women who undergo breast recon-
struction. Unfortunately, most studies that have
compared the QOL impact between BCS and
mastectomy have not had sufficient sample sizes to
examine outcomes between women who received
mastectomy only from those who received mas-
tectomy with reconstruction. Findings have been
mixed in studies that addressed reconstruction.
For example, Ganz et al. [9] found no significant
differences between mastectomy only and mastec-
tomy with reconstruction. Schover and colleagues
[7] found no differences between mastectomy with
reconstruction and BCS, while Nissen et al. [18]
found that those who received breast reconstruc-
tion reported lower scores on physical, emotional,
and functional well-being compared to those who
received mastectomy only. In a large study of
women from two metropolitan areas, Rowland
et al. [15] found that women who received mas-
tectomy with or without reconstruction did not
differ from those receiving BCS on emotional,
social or role function, but did report more phys-
ical symptoms. Additionally, women with recon-
struction were significantly more likely to report
that breast cancer had a negative impact on their
sex lives.
Fewer studies have focused on the QOL impact
of treatment options beyond the primary surgical
procedure. The increasing use of adjuvant che-
motherapy in women who obtain small incre-
mental survival benefits [19, 20] requires an
understanding of the QOL impact of this treat-
ment to fully inform women of the risks and
benefits. For example, Schover et al. [7] found that
after 4 years, women who underwent chemother-
apy had more dysfunction, worse body image, and
more psychological distress. Ganz et al. [9] found
that both physical and sexual functioning were
worse for women who received chemotherapy,
independent of the type of surgery performed.
The impact of breast cancer treatment on pop-
ulation subgroups has usually involved a focus on
one or a limited number of sociodemographic
characteristics. Some studies have examined age
differences [21–23], and other demographic char-
acteristics, for example race differences [22, 24, 25].
However, most publications are based on rela-
tively small, homogeneous convenience samples
which limit their power to examine a variety of
sociodemographic characteristics simultaneously.
Furthermore, QOL is assessed differently reducing
comparability between studies. Although time
from treatment is an important independent vari-
able [12], many studies have not controlled for
wide variations in elapsed time since surgery
within studied groups. This study seeks to address
some of the gaps in the literature by using a large
population-based sample that over-sampled for
women with DCIS and for African American
women in order to focus on answering the fol-
lowing questions.
1. Is there a relationship between cancer stage at
diagnosis and various dimensions of QOL
independent of breast cancer treatment re-
ceived?
2. What is the relationship of primary surgical
treatments for breast cancer on various
dimensions of QOL, and does it differ between
women who received mastectomy only and
those who received breast reconstruction?
3. What is the relationship of chemotherapy (for
women with Stage I and II) and radiation
therapy on QOL and does it differ depending
on initial surgical treatment?
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4. Are sociodemographic characteristics associ-
ated with QOL, and do they modify the ob-
served relationships between treatment for
breast cancer and QOL?
Methods
Study population
The study population consisted of women diag-
nosed with DCIS and invasive, nonmetastatic
breast cancer in Detroit, Michigan and Los
Angeles, California. Eligibility criteria included:
(1) age 6 79 years, (2) a primary diagnosis of
breast cancer treated with a definitive surgical
procedure, (3) residing in the catchment area of the
Detroit and Los Angeles Surveillance Epidemiol-
ogy and End Results (SEER) sites and, (4) capable
of completing a written or telephone survey in
English or Spanish. Only women who completed
the written survey were included as the telephone
survey lacked the primary QOL measures. Asian
women in Los Angeles were also excluded due to
participation in competing studies. Women were
also excluded who had: a previous history of pri-
mary breast cancer; presented with metastatic
disease; or, had a diagnosis of lobular carcinoma
in-situ.
Data collection procedures
Women were identified from SEER registries in
Detroit and Los Angeles between December 2001
and January 2003. Most cases of breast cancer
were identified within 6 weeks of initial diagnosis.
All cases of DCIS and an approximate 20% ran-
dom sample of invasive cases were selected in both
cities. African American women with invasive
disease were over sampled to increase their repre-
sentation to approximately one-third in Detroit
and 20% in Los Angeles.
Once SEER registries identified potential par-
ticipants, physicians were notified of our intent to
contact patients and less than 1% were excluded
because of physician concerns. An introductory
letter was sent to potential subjects followed by a
phone call to assess eligibility. Questionnaires and
a $10 gift were mailed to all who agreed to par-
ticipate over the phone and to women who could
not be reached by phone (approximately 7% of
potential respondents). The Dillman method was
used to encourage response rates [26], involving a
postcard reminder for non-respondents at
2 weeks, a second letter and survey at 6 weeks, and
a follow-up phone call at 10 weeks. At the follow-
up phone call non-responders were offered, if they
preferred, a short telephone survey.
After removing identifying information, com-
pleted surveys were forwarded to the University of
Michigan investigators for data entry and analysis.
Subsequently, SEER pathology and survey data
were merged using a unique patient identification
number. The study protocol was approved by the
Institutional Review Boards of the University of
Michigan, Wayne State University, and the Uni-
versity of Southern California.
Study measures
Sociodemographic characteristics: Survey items
included age at breast cancer diagnosis, race,
education level, employment status, income, and
marital status.
Prior health status: The standard self-rated
health question was modified as follows: ‘‘Before
you were told you have breast disease, would you
say your health was: poor, fair, good, very good or
excellent.’’ Self-rated health has been strongly and
independently associated with morbidity and
mortality [27]. We also asked about the presence of
six chronic conditions: chronic bronchitis, heart
disease, diabetes, high blood pressure, stroke, and
arthritis.
Clinical factors: Breast cancer stage was classi-
fied using the American Joint Committee on Cancer
(AJCC) TNM Staging System for Breast Cancer
and SEER summary data. Only women with
Stages 0–II were included.
Breast cancer treatment: Participants were asked
the type of surgical treatment received: breast
conserving surgery, mastectomy only, and mas-
tectomy with breast reconstruction.
Additional treatments: Survey items inquired
about ongoing or completed treatment including
chemotherapy, radiation therapy, and/or hormone
(endocrine) therapy.
Missing self-reported information was updated
using SEER summary information for the fol-
lowing measures: age at diagnosis, race, marital
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status, response time from diagnosis, primary
surgical treatment, chemotherapy, and radiation
therapy.
Health-related quality of life: The European
Organization for the Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) [28] and the Breast Cancer-Specific
Quality of Life Questionnaire (QLQ BR-23) [29]
were used to assess QOL. The EORTC QLQ-C30
version 2 contains 30 questions addressing: five
functional domains; one global QOL item; three
symptom scales; and, six single items assessing
financial impact and physical symptoms using ‘‘the
past week’’ as a time frame. The format utilized
yes/no, 4-point response, and visual analogue
scales. The QLQ-BR23 consists of 23 items
including two functional scales on body image and
sexual functioning. The body image subscale in-
quires about feeling less attractive, feeling less
feminine, difficulty looking at oneself naked, and
dissatisfaction with ones body. The sexual func-
tioning scale asks (over the past month) about
interest in sex, and the extent to which women
were sexually active, with or without intercourse.
The QLQ-BR23 also contains three symptom
scales and three single items. The psychometric
properties of the EORTC QLQ-C30 [30–33] and
the QLQ-BR23 [29] have been previously estab-
lished with excellent reliability and validity and
have been used with breast cancer patients [34–35].
Consistent with recommendations by Sprangers
[29], a limited set of subscales and items of prime
interest were identified a priori. Nine QOL mea-
sures were chosen from the two instruments
including: physical, social, emotional, and role
functional domains and domains relevant for wo-
men being treated for breast cancer (fatigue, body
image, future perspective, sexual functioning, and
sexual enjoyment). Using the EORTC QLQ-C30
scoring algorithm all QOL measures range from 0
to 100. Higher scores represent a higher level of
functioning for functional measures and a lower
level for symptom measures. Because fatigue was
the only symptom measure examined in this study,
for ease of interpretation, we transformed fatigue
scores such that higher scores always indicate
better QOL.
A major advantage of the EORTC QLQ-C30 is
the considerable work that has been published on
interpretation of clinically relevant difference
scores [36–37]. Osoba et al. [37] found that pa-
tients with breast and lung cancer who perceived a
‘‘moderate change either better or worse’’ over
time also reported a corresponding mean change
of 10–20 points on their EORTC QLQ-C30 scores.
Based on that study, we set the criteria of a be-
tween-group difference of 10 points or more to
represent a ‘‘clinically meaningful difference.’’ [37].
Statistical methods
Each QOL measure was standardized into a score
of 0 to 100 by using a linear transformation as
instructed by the EORTC QLQ-30 Scoring Man-
ual. The reliability of all scales was assessed by
using Cronbach’s alpha coefficient.
Bivariate associations were investigated between
stage and treatment and each of the QOL mea-
sures, using Analysis of Variance (ANOVA).
Multivariable models were analyzed using Analy-
sis of Covariance (ANCOVA) to test for adjusted
associations among treatment, sociodemographic
characteristics, and QOL measures. Models were
constructed with each QOL measure as separate
outcomes and included all sociodemographic
variables, prior health status, clinical, stage, and
treatment variables. Sample weights were included
to adjust for design effects resulting from our dif-
ferential sampling across race and stage. Interac-
tions between treatment and sociodemographic
characteristics were assessed separately and re-
tained if the p value < 0.05. All significant inter-
actions were assessed simultaneously in the final
model and only interactions that maintained sig-
nificance (p < 0.05) were retained. Of primary
interest were results that were both statistically
significant and clinically meaningful, based on the
Osoba et al. 10 point criteria [37]. Because all
hypotheses were specified a priori no adjustments
were made for multiple comparisons. However, a
p value O 0.001 can be viewed as statistically
significant by the most conservative methods of
adjustments for multiple comparisons. All analy-
ses were performed using SAS version 8.2.
Results
We accrued 2640 cases prospectively into the
preliminary study sample. Approximately 88%
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of cases initially identified by the registries were
eligible and 74.3% of those eligible completed
the survey (93% completed the written survey
and 7% an abbreviated telephone survey). Non-
respondents were older, more likely to be non-
white, and more likely to have advanced stage.
Nonrespondents were also somewhat more likely
to receive mastectomy (35% vs. 31%), although
the difference was not statistically significant
(p ¼ 0.06). We excluded 141 women with late
stage disease (Stage III, IV), and 184 women
who had not completed primary treatment (sur-
gery, chemotherapy, and radiation therapy), of
the 1682 eligible participants. Those who were
excluded for late stage disease or because they
had not completed treatment were more likely to
be younger, African American, and never mar-
ried. The final sample for this study included
1357 women with Stage 0–II breast cancer (96%
completed the survey in English and 4% in
Spanish).
Table 1 describes characteristics of the study
participants overall, and by primary surgery. The
mean age of the subjects was 60.0 years (range
27.9–79.9), with 68% Caucasian, 19% African
American, and 13% ‘‘other’’ (80% Hispanic).
Average co-morbidities reported was 1.1 and
over half of the women reported a very good or
excellent health status at diagnosis. Using AJCC
criteria, 44% of women had Stage 0, 47% had
Stage I, and 27% had Stage II breast cancer.
Approximately 68% of women received BCS,
18% received mastectomy only, and 13% had
mastectomy with reconstruction. About 21% of
women in the final sample completed chemo-
therapy (34.0% with Stage I and II breast can-
cer), 57% completed radiation therapy, and 52%
started on hormone therapy. Women who re-
ceived mastectomy with reconstruction were
younger, more educated, and reported few co-
morbidities than women receiving BCS or mas-
tectomy only. Women who had either BCS or
mastectomy with reconstruction were more likely
to be white, have higher income, and lower
cancer stage at diagnosis than those women who
had mastectomy only.
The internal reliability of six QOL outcomes
(emotional, role, social, and sexual functioning,
fatigue, and body image) yielded a Cronbach’s
alpha P 0.80, with physical functioning
somewhat lower (alpha ¼ 0.70). Sexual enjoyment
and future perspective were single item measures.
ANCOVA models were used to determine the
mean scores for the nine QOL outcomes by cancer
stage at diagnosis, controlling for study site, prior
health status, primary surgical treatment received,
response time since treatment, and other treat-
ments received. The results revealed no clinically
meaningful differences in any of the QOL outcome
scores when comparing Stage 0 vs. Stage I–II. All
further analyses exploring the relationship of var-
ious aspects of treatment to QOL controlled for
cancer stage at diagnosis.
Figure 1 presents results of ANCOVA models
used to determine the mean scores for the nine
QOL outcomes by primary surgical treatment re-
ceived, controlling for all other factors. A mean-
ingful difference in QOL was observed in body
image with those who received BCS reporting
higher scores on body image than those receiving
mastectomy with reconstruction. No other clini-
cally meaningful differences were observed by
primary surgical treatment, although women with
reconstruction had lower QOL scores on all mea-
sures except sexual functioning and sexual enjoy-
ment. No meaningful differences were detected in
QOL dependent on receipt of radiation (not
shown).
Figure 2 displays mean scores for the QOL
dimensions among women with Stage I or II
breast cancer who received chemotherapy vs. no
chemotherapy. Using ANCOVA models, four
meaningful QOL differences were identified.
Women who received chemotherapy compared
to no chemotherapy reported lower QOL scores
on social well being, fatigue, body image, and
future perspective.
Table 2 describes QOL scores after breast cancer
according to selected sociodemographics with bol-
ded numbers representing statistically significant
and clinically meaningful results. Age at diagnosis
was statistically significant and clinically meaning-
ful for six of nine QOL outcomes. Except for sexual
functioning and sexual enjoyment, women over 70
reported higher scores than younger women, while
women under 70 reported greater sexual function-
ing and more sexual enjoyment. For role func-
tioning African American women reported lower
scores than white women, and for sexual enjoy-
ment, respondents who were divorced, widowed,
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Los Angeles 712 52 54 54 44 0.05
Detroit 645 48 46 46 56
Age
Mean (SD)a 1357 60.0 (11.3) 60.7 (11.1) 62.8 (10.4) 52.8 (10.4) <0.0001
<50 yrs 281 21 19 13 41
50–70 yrs 777 57 58 59 53
>70 yrs 299 22 23 28 6
Race
Caucasian 915 68 70 54 76 <0.0001
African American 256 19 18 28 13




162 12 10 23 7 <0.0001
High school diploma 299 22 23 26 12
Some college 508 38 39 33 40
College Graduate
and beyond
375 28 28 18 41
Employed
Yes 633 48 48 33 65 <0.0001
No 696 52 52 67 35
Income
<$20,000 267 20 18 32 11 <0.0001
$20,000–$49,999 381 28 28 33 23
>=$50,000 560 41 42 24 59




807 59 60 51 68 0.02
Divorced/separated/
widowed
445 33 32 40 26
Never married 105 8 8 9 6
Prior health status
Number of co-morbiditiesa 1354 1.1 (1.1) 1.0 (1.1) 1.4 (1.2) 0.8 (1.0) <0.0001
Health status at diagnosis
Poor/fair 166 12 11 22 6 <0.0001
Good 443 33 34 40 23
Very good/excellent 729 55 55 38 71
Clinical factors
Stage
Stage 0 555 44 44 35 56 <0.0001
Stage I 462 37 40 35 25
Stage II 239 19 16 30 19
Time from treatmenta 1284 7.1 (2.6) 7.1 (2.5) 7.1 (2.7) 6.8 (2.8) 0.2
Treatment
Chemotherapyb
No 1064 79 82 73 78 0.008
Yes 277 21 18 27 22
Radiation therapyb
No 580 43 21 87 96 <0.0001
Yes 776 57 79 13 4
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separated, or never married reported lower scores
than respondents who were currently married.
The main-effects modeling also provides infor-
mation on whether the sociodemographic factors
confound the relationship among primary surgical
treatment, chemotherapy, and QOL. After con-
trolling for such factors, clinically meaningful
differences dependent on surgical treatment and
chemotherapy reported in Figures 1 and 2 remain
for body image. However, observed differences in
social functioning, fatigue, and future perspective
with chemotherapy were reduced with sociode-
mographic factors in the model. Women who
received a mastectomy with reconstruction con-
tinued to have the lowest QOL dimension scores
for all outcomes (excluding sexual functioning and
sexual enjoyment).
The extent to which sociodemographic factors
modified the relationships among primary surgical
















No 648 48 47 50 55 0.09
Yes 691 52 53 50 45
aMean (SD = standard deviation) reported for continuous variables.
bFor chemotherapy and radiation therapy yes indicates number of women who have completed treatment.
cFor hormone therapy yes indicates number of women who have started or finished treatment.










BCS (N=928) Mastectomy only (N=238) Mastectomy w/reconstruction (N=182)
+
*
Figure 1. Mean quality of life dimension scores by primary surgical treatment. The figure controls for study site, health status at
diagnosis, number of co-morbidities, response time from initial treatment, stage, chemotherapy, radiation therapy, and hormone
therapy.
+Restricted to respondents who reported being sexually active.
Statistically significant findings: p value 6 0.05: Role Functioning, Future Perspective, Sexual Functioning; p value 6 0.01: Emo-
tional Functioning, Fatigue; p value 6 0.001: Social Functioning, Body Image.
*Indicates a statistically significant and clinically meaningful difference: Body Image: BCS > Mastectomy w/reconstruction.
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examined. Figure 3 summarizes the significant
interactions found with chemotherapy (for women
with Stage I and II) and level of education. Level
of education modified the relationship between
chemotherapy and QOL for the functional scales
excluding physical functioning. In particular, for
role and social functioning, there was a gradient of
higher levels of QOL with increasing levels of
education for women who received chemotherapy.
While emotional functioning did not have the
same gradient, a trend of better QOL scores for
women who received chemotherapy and had the
highest level of education was observed. Addi-
tional interactions were observed for primary
surgical treatment and chemotherapy for emo-
tional functioning, social functioning, and body
image (not shown). For social functioning, women
who had mastectomy (with or without recon-
struction) as well as chemotherapy reported higher
QOL scores than women who had the combina-
tion of BCS and chemotherapy. The opposite
pattern was observed for body image with BCS
and chemotherapy a better combination than
mastectomy and chemotherapy. No significant
interactions were observed for radiation therapy.
Discussion
The results of this population-based study provide
further insight into the impact of early stage breast
cancer and its treatment on QOL, and the extent
to which the impact differs across sociodemo-
graphic subgroups. There were no meaningful
differences between cancer stage at diagnosis and
QOL, independent of cancer treatment. These
findings support earlier studies [3, 4] suggesting
that despite the excellent prognosis for women
with Stage 0, the diagnosis of breast cancer is
stressful, and may result in a pattern of psycho-
logical morbidity for these women similar to that
experienced by women with invasive disease.
The large sample allowed for comparisons across
surgical treatment groups including BCS, mastec-
tomy only, and mastectomy with reconstruction.
















Figure 2. Mean quality of life dimension scores by receipt of chemotherapy for women with stage I or II breast disease. The figure
controls for study site, health status at diagnosis, number of co-morbidities, response time from initial treatment, stage, primary
surgical treatment, radiation therapy, and hormone therapy.
+Restricted to women who reported being sexually active.
Statistically significant findings: p-value < 0.05:Physical and Emotional Functioning;
p value < 0.01: Role Functioning; p value < 0.001: Social Functioning, Fatigue, Body Image, Future Perspective.
*Indicates a statistically significant and clinically meaningful difference.
Note: Differences for social functioning, fatigue, and future perspective remained statistically significant but differences were less than


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Consistent with many previous reports [8–10, 15]
few differences were observed across surgical op-
tions for a multitude of QOL dimensions. It ap-
pears that mastectomy only does not substantially
reduce QOL compared to BCS, with the exception
of body image. Women should be reassured that
mastectomy is a reasonable choice in terms of both
survival and major dimensions of QOL.
Similar to findings of Rowland et al. [15] when
asked about body image and feeling physically
less attractive, this study found QOL scores for
women undergoing breast reconstruction were
more similar to those receiving mastectomy only
than those undergoing BCS. Although body
image was the only outcome that constituted a
clinically meaningful difference, women with
breast reconstruction had lower QOL scores for
seven QOL dimensions assessed. Other research
has produced mixed results on the benefits of
breast reconstruction [7, 15, 18, 38–40]. Consis-
tent with findings of Zweiler et al. [39], women
who received reconstruction reported QOL
scores as high as women receiving BCS for
sexual functioning and enjoyment. Another study
found that women with reconstruction were the
most likely to feel that breast cancer had a
negative impact on their sex lives [15].
There are several possible explanations for the
generally lower QOL scores observed in this study
among women with breast reconstruction. QOL
assessment occurred early in the treatment recov-
ery period, and breast reconstruction may not be
complete for a year or longer depending on the
number of procedures required. In studies with
follow-up over two years after diagnosis, Rowland
et al. [15] reported differences in body image and
sexuality persist, while Schover et al. [7], found no
significant differences in psychosocial adjustment,
body image or sexual life between women who
underwent BCS compared to those with mastec-
tomy and reconstruction. In addition, women
receiving reconstruction include a subset of women
who preferred BCS, but were not good candidates
for the procedure. These women may have more
difficulty coping with the body image and cosmetic
results than women who chose mastectomy with
breast reconstruction. However, women who
chose reconstruction were no more likely to report
decisional regret, and were slightly more satisfied
with the surgical decision than women undergoing
mastectomy only [41]. Nonetheless, the results
suggest that women electing reconstruction should
be informed of the short-term QOL impact of































































Less than high school High school diploma College and beyond
Emotional   Role   Social 
Figure 3. Mean quality of life score by receipt of chemotherapy and level of education for women with stage I, or II disease.
Means are adjusted for all other main effects including study site, age, race, employment status, income, health status at diagnosis,
number of co-morbidities, response time from initial treatment, primary surgical treatment, radiation therapy, and hormone therapy
Emotional functioning p value ¼ 0.001; Role functioning p value ¼ 0.04; Social functioning p value ¼ 0.007.
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in the length of the recovery process and uneven
cosmetic results [18, 40].
The findings also suggest that adjuvant chemo-
therapy had a greater impact on QOL than which
surgical procedure was performed. While the
largest QOL differences were found in areas of
body image and future perspective, meaningful
differences were also observed in social well-being
and fatigue. Schover et al. [7] also found few dif-
ferences in overall psychosocial adjustment
dependent on surgical choice but more psycho-
logical distress and poorer body image in women
who had chemotherapy. Lower scores may be
attributed to issues surrounding hair loss and
malaise that persist for months after chemother-
apy is completed. The onset of menopausal
symptoms with chemotherapy has also been found
to cause disruption in the sexual lives of younger
women [42]. Contrary to previous studies sup-
porting the negative effect of chemotherapy on
sexual functioning [9, 38, 43] this study did not
find meaningful differences in sexual functioning
or sexual enjoyment among women by receipt of
chemotherapy.
The evidence is compelling that the impact of
breast cancer on QOL is more profound in youn-
ger women. In four of nine QOL outcomes (emo-
tional and social functioning, body image, and
future perspective) younger women reported lower
scores than women over 70 years of age. This
disproportionate negative impact of breast cancer
on younger women has been reported elsewhere
[22, 23, 44–46]. Explanations for this observation
include that younger women may: experience more
discordance between their health expectations and
their current situation resulting in feelings of
greater vulnerability and impact on their QOL [21,
44]; experience greater disruptions in their daily
lives, work schedules and, financial stability [44];
possess fewer coping strategies and resources to
manage life-threatening illness; and, experience a
menopausal transition associated with poorer
health perceptions and reduced vitality [22]. Our
findings cannot totally be explained by the fact
that younger women may receive more aggressive
treatment, since treatment was controlled for in all
analyses examining sociodemographic differences.
In contrast to age-related QOL differences, few
clinically important QOL differences were
observed by race. Our findings are consistent with
Pikler et al. [47] but contrary to several recent
studies [20, 22, 23] suggesting that African Ameri-
can women may fare better than whites. African
American women may utilize more religious-
oriented coping and other coping strategies than
whites and other ethnic groups, as well as find more
meaning in life after breast cancer [22, 24, 48].
Of some concern were findings that receipt of
chemotherapy had a disproportionately greater
impact on women with lower levels of education.
Other studies reporting a similar association be-
tween education and physical and psychosocial
concerns following breast cancer [7, 49], suggest
that education may provide a buffer to the nega-
tive impact of breast cancer [49]. In this study,
women who reported having less than a high
school diploma were also more likely to be
minority (in particular, non-English speaking
Hispanics), of lower income, and unemployed.
Further research should explore factors that may
contribute to this finding (e.g., acculturation,
reading levels and cultural relevance of health
communications, availability of bilingual health
educators, patient-provider communication, and
mistrust of the medical care system).
Study findings are limited by the cross-
sectional design and lack of baseline QOL
assessment prior to the breast cancer diagnosis.
However, health status prior to cancer diagnosis
and number of co-morbidities were controlled
for in all analyses. In addition, the generaliz-
ability of findings to non-white ethnic groups is
somewhat compromised by the practical limita-
tion posed by exclusion of Asian women at one
site and the relatively small sample of ethnic
groups outside of African Americans. Future
research should actively recruit women from a
variety of ethnic backgrounds to explore the
extent to which ethnicity predicts QOL and/or
moderates the relationships between treatment
and QOL. While a degree of arbitrariness is
inherent in the decision to choose a ten point
difference between groups to designate a clini-
cally meaningful difference in QOL, this decision
was based on previous work by Osoba et al. [37],
and avoids the pitfalls of a large sample size
yielding statistically significant findings that are
likely not to be clinically meaningful.
In summary, the findings from this population-
based study have implications for clinical practice
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and future research. Mastectomy and BCS are
essentially equivalent choices in terms of QOL
with the exception of the impact on body image.
For some women, body image is a major consid-
eration in choice of therapy, while for others
concerns about recurrence or treatment duration
predominate. More research is needed to sort out
when the QOL benefits of breast reconstruction
emerge over time, but clinicians should present
both the short and long term QOL impact of
breast reconstruction to patients. More research is
needed to evaluate the impact of chemotherapy on
QOL, especially in potentially vulnerable popula-
tions. Finally, we need to identify and target wo-
men disproportionately affected by breast cancer
such as younger women and those with lower
education levels, and develop behavioral and
counseling interventions that address their unique
issues and concerns.
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